Skip to main content
. 2023 Apr 19;76(Suppl 1):S66–S76. doi: 10.1093/cid/ciac969

Figure 4.

Figure 4.

Proportion of Shigella serogroups from stools of cases of moderate-to-severe diarrhea at the 3 Vaccine Impact on Diarrhea in Africa (VIDA) study sites. The frequency of Shigella-positive cases during 3 study periods (Global Enteric Multicenter Study [GEMS], GEMS-1A, and VIDA) is shown for each of the 3 study sites in sub-Saharan Africa.